ASH 2021 | MPNs at ASH: pelabresib updates

I’m looking forward to seeing updates on ongoing studies, anything new that’s emerging from either preclinical or early based clinical trial. I think one drug that has maintained its interest level and excitement is pelabresib, the oral pan-BET inhibitor. So one abstract to look out for is an abstract presented by my colleague, Marina Kremyanskaya, which is an update on the clinical activity of pelabresib, which has been really very impressive, particularly in the JAK-inhibitor treatment naive patients in which we’re seeing SVR of 35% rates of 67% and very impressive TSS 50% rates with a subset of patients that can attain bone marrow fibrosis reduction anemia responses. And what I’m hopeful for is that the ongoing MANIFEST-2, which is the randomized Phase III study in JAK-inhibitor naive patients will hit very key primary and secondary endpoints of spleen volume response, symptom improvement, but most importantly, durability of response, that we can extend the benefit of single agent ruxolitinib so that patients can enjoy that benefit for longer and delay the potential for discontinuation and the bad outcomes that we’ve discussed when patients unfortunately discontinue a JAK-inhibitor.